Table 1.
Baseline characteristics.
| ALS n = 39 |
ALS-Cog n = 10 |
ALS-FTD n = 12 |
Controls n = 30 |
p-value | Post hoc test | |
|---|---|---|---|---|---|---|
| Age in years | 61.6 ± 11.3 | 65.4 ± 9 | 65.3 ± 11.6 | 62.8 ± 9.9 | 0.523 | NA |
| Gender (%male) | 61.5% | 20% | 66.7% | 40% | 0.043 |
ALS-Cog < ALSa ALS-Cog < ALS-FTDa |
| Years of education | 11.9 ± 2.2 | 10.1 ± 2.6 | 13.2 ± 4.4 | 0.119 | NA | |
| FVC | 80.1 ± 16.5 | 71.9 ± 24.9 | 62.7 ± 16.5 | 0.036 | ALS > ALS-FTDb | |
| Disease duration (months) | 23.3 ± 21.5 | 15.5 ± 8.2 | 23 ± 12.2 | 0.502 | NA | |
| ALSFRS-R | 42.7 ± 3.6 | 37.9 ± 7.8 | 39.6 ± 5.4 | 0.079 | NA | |
| ALSFRS-R bulbar | 10.3 ± 2 | 8.4 ± 1.9 | 9.8 ± 2.6 | 0.044 | NS | |
| ALSFRS-R fine motor | 10.8 ± 1.7 | 10 ± 2.4 | 8.5 ± 2.6 | 0.037 | ALS > ALS-FTDb | |
| ALSFRS-R gross motor | 10.4 ± 1.9 | 9.2 ± 3.4 | 9.9 ± 2.9 | 0.809 | NA | |
| ALSFRS-R respiratory | 11.5 ± 0.9 | 10.3 ± 2.4 | 11.2 ± 1.7 | 0.314 | NA | |
| Progression rate | 0.37 ± 0.35 | 1 ± 1.3 | 0.5 ± 0.5 | 0.209 | NA | |
| Limb onset | 68.4% | 20% | 50% | 0.020 | ALS-Cog < ALSa | |
| MRC sum score | 81.7 ± 7.5 | 82.9 ± 5.5 | 81 ± 8.7 | 0.718 | NA | |
| MRC UL score | 54.6 ± 6.1 | 55.7 ± 4.1 | 52.7 ± 7.2 | 0.728 | NA | |
| MRC LL score | 27.1 ± 7.3 | 27.2 ± 1.6 | 28.3 ± 2.4 | 0.285 | NA | |
| MRC APB score | 4.5 ± 0.5 | 4.7 ± 0.5 | 4.4 ± 0.5 | 0.476 | NA | |
| UMN score | 9.6 ± 4.3 | 5.7 ± 5.9 | 8.8 ± 5.6 | 0.175 | NA | |
| Riluzole therapy % | 52.6% | 44.4% | 33.3% | 0.496 | NA |
Table showing clinical features including motor features and functional scores on various subdomains of the Amyotrophic lateral sclerosis functioning rating scale—revised version (ALSFRS-R).
ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; MRC score, Medical Research Council score; UMN score, upper motor neuron score; UL, upper limb; LL, lower limb; FVC, forced vital capacity; NA, not applicable.
a0.01 < p < 0.05; b0.001 < p < 0.01; cp < 0.001, NA = not applicable, all mean variables presented as mean ± SD.